These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23409798)

  • 1. HIV type-1 group O infection in Gabon: low prevalence rate but circulation of genetically diverse and drug-resistant HIV type-1 group O strains.
    Liégeois F; Boué V; Butel C; Mouinga-Ondémé A; Sica J; Zamba C; Peeters M; Delaporte E; Rouet F
    AIDS Res Hum Retroviruses; 2013 Jul; 29(7):1085-90. PubMed ID: 23409798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High HIV Type 1 prevalence and wide genetic diversity with dominance of recombinant strains but low level of antiretroviral drug-resistance mutations in untreated patients in northeast Gabon, Central Africa.
    Mintsa-Ndong A; Caron M; Plantier JC; Makuwa M; Le Hello S; Courgnaud V; Roques P; Kazanji M
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):411-8. PubMed ID: 19320567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).
    Scherrer AU; Hasse B; von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Bucher HC; Ledergerber B; Günthard HF
    HIV Med; 2009 Nov; 10(10):647-56. PubMed ID: 19732174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania.
    Fall-Malick FZ; Tchiakpé E; Ould Soufiane S; Diop-Ndiaye H; Mouhamedoune Baye A; Ould Horma Babana A; Touré Kane C; Lo B; Mboup S
    J Med Virol; 2014 Mar; 86(3):404-10. PubMed ID: 24318486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.
    Ceccarelli L; Salpini R; Moudourou S; Cento V; Santoro MM; Fokam J; Takou D; Nanfack A; Dori L; Torimiro J; Sarmati L; Andreoni M; Perno CF; Colizzi V; Cappelli G
    J Med Virol; 2012 May; 84(5):721-7. PubMed ID: 22431019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun.
    Vessière A; Rousset D; Kfutwah A; Leoz M; Depatureaux A; Simon F; Plantier JC
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):107-10. PubMed ID: 19770803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M.
    Depatureaux A; Charpentier C; Leoz M; Unal G; Damond F; Kfutwah A; Vessière A; Simon F; Plantier JC
    J Acquir Immune Defic Syndr; 2011 Feb; 56(2):139-45. PubMed ID: 21233638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Diversity and Drug Resistance Among Antiretroviral Treatment-Failed Individuals from 2010 to 2012 in Honghe, China.
    Yang C; Yang S; Li J; Yang B; Liu J; Li H; Bian Z
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):822-9. PubMed ID: 25919896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon.
    Nzengui-Nzengui GF; Mourembou G; M'boyis-Kamdem H; Kombila-Koumavor AC; Ndjoyi-Mbiguino A
    BMC Infect Dis; 2024 Mar; 24(1):316. PubMed ID: 38486188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
    Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
    Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of genotypic resistance to nucleoside analogues, nonnucleoside analogues, and protease inhibitors in HIV-infected persons in Athens, Greece.
    Panos G; Charatsis G; Paparizos V; Kazantzi M; Falagas ME
    AIDS Res Hum Retroviruses; 2008 Jan; 24(1):43-51. PubMed ID: 18275347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand.
    Le Nguyen H; Pitakpolrat P; Sirivichayakul S; Delaugerre C; Ruxrungtham K
    J Med Virol; 2012 May; 84(5):713-20. PubMed ID: 22431018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
    Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
    HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy.
    Lihana RW; Khamadi SA; Lubano K; Lwembe R; Kiptoo MK; Lagat N; Kinyua JG; Okoth FA; Songok EM; Makokha EP; Ichimura H
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1211-7. PubMed ID: 19954302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short communication: high natural polymorphism in the gag gene cleavage sites of non-B HIV type 1 isolates from Gabon.
    Liégeois F; Reteno DG; Mouinga-Ondémé A; Sica J; Rouet F
    AIDS Res Hum Retroviruses; 2013 Aug; 29(8):1179-82. PubMed ID: 23551028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of partial pol and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon.
    Pandrea I; Robertson DL; Onanga R; Gao F; Makuwa M; Ngari P; Bedjabaga I; Roques P; Simon F; Apetrei C
    AIDS Res Hum Retroviruses; 2002 Oct; 18(15):1103-16. PubMed ID: 12396449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
    Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D
    J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic analysis of HIV type 1 strains from newly infected untreated patients in cyprus: high genetic diversity and low prevalence of drug resistance.
    Kousiappa I; van de Vijver DA; Demetriades I; Kostrikis LG
    AIDS Res Hum Retroviruses; 2009 Jan; 25(1):23-35. PubMed ID: 19182918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.